Identification of KCNJ5 gene an adverse prognosis associated novel onco-ionchannel in Indian pancreatic cancer cohort

• DOI: 10.1007/s12672-025-02001-8
• Publication Date: 2025-02-25T14:14:12Z
• Authors: Akash Bararia; Arunima Maiti; Gourav Ghosh; Deepyaman Das; Debabrata Ghosh D...; Sumit Mukherjee; Shibajyoti Ghosh; Bitan K. Chattopa...; Sudeep Banerjee; Supriyo Ghatak; Nilabja Sikdar
• Keywords: Identification

Pancreatic cancer (PanCa) is one of the most lethal cancers (survival ~ 12%). As conventional therapeutic interventions are mostly futile, a deep understanding disease pathophysiology an urgent need. Ion channels, located on cell membrane, contribute significantly to hallmarks, through dysregulation various ion translocation; however, fundamental mechanisms remain uncertain. To identify these oncochannels in Indian cohort PanCa, we utilized 450 K data, published our previous study, and identified potential pathways involved. Their expressions were evaluated using TCGA data independent paired patient (n = 20). The top genes further validated GEO ScRNA seq dataset. Potential target ability KCNJ5 was molecular dynamic based drug designing. A set 7 differentially methylated expressed ion-channel proteins namely KCNJ5, CACNB2, KCNA3, KCNA6, RASA3, GABBR2 CLIC5 PanCa only. upregulated associated with worse survival cohort, whereas downregulated other Caucasians populations. Two TFs controlling expression POU2F1 POU3F1. Few predicted small molecules targeting Kcnj5 are, Amiloride, Vernakalant hydrochloride, Dalfampridine, Glyburide Levcromakalim. It also showed notable interactions steroidal anticancer agent, protodioscin. An onco-channel gene, upregulated, showing adverse highly group can be targeted Levcromakalim This lead novel identification for therapy development.